St. Jude Medical
St. Jude Medical is expanding its cardiac resynchronization therapy portfolio with SyncAV CRT software, which just received CE mark approval. The software builds on the company's MultiPoint Pacing tech.
St. Jude Medical has been working for a couple of years to make the case for its tiny implantable heart failure monitor CardioMEMS--without much sales success thus far. But it gained a bit more fodder with the inclusion of the device to the European Society of Cardiology guidelines as a recommended tool to diagnose and treat acute and chronic heart failure.
Abbott and Alere aren't on the same page regarding the former's $5.8 billion acquisition of the latter. Abbott announced on Wednesday that it is auditing Alere's books, while the diagnostics maker--despite being under a federal investigation for its international sales practices--said it still expected the acquisition to close as planned.
It's been a long road for St. Jude Medical with its stroke prevention device, but the company is celebrating a milestone after an FDA panel recommended the product for approval.
Otsuka has given renal denervation to treat hypertension another vote of confidence. It's signed a distribution deal for certain Asian companies with startup ReCor Medical, as well as making an additional investment in the company.
St. Jude Medical presented data on its leadless pacemaker and cited two other presentations given at this year's Heart Rhythm Society gathering that demonstrated the Nanostim device can be successfully retrieved from patients without serious adverse complications.
Abbott Laboratories is seeking a new path to growth--and it's betting big that med tech is it. The company is taking on two of the largest M&A transactions in history at the same time: the more than $5.8 billion purchase of diagnostics player Alere that it announced at the start of February and the more than $25 billion buy of cardiovascular device player St. Jude Medical that was disclosed in late April.
The medical device industry has been working on miniaturizing pacemakers so they can be minimally invasively inserted and cause fewer difficulties for patients. Up next likely are closed-loop systems: pacemakers that record patient data, transmit that data externally and enable adjustment based on that data by physicians or even, eventually, on their own as guided by advanced algorithms.
Chinese TAVR player buys German third-gen peer, aims for global market after $37M from Goldman Sachs
Venus Medtech aims to have the first transcatheter aortic valve implantation system cleared by the China Food and Drug Administration (CFDA). It also has a transcatheter pulmonic valve that is finishing clinical trials, which would also be a first for the CFDA.
St. Jude Medical has launched its Axium Neurostimulator System for dorsal root ganglion stimulation to treat patients with chronic pain.